Horizon Discovery Group PLC (LON: HZD) has recently received a number of price target changes and ratings updates:

  • 9/21/2016 – Horizon Discovery Group PLC had its “speculative buy” rating reaffirmed by analysts at Beaufort Securities.
  • 9/20/2016 – Horizon Discovery Group PLC had its “buy” rating reaffirmed by analysts at N+1 Singer. They now have a GBX 194 ($2.53) price target on the stock.
  • 9/20/2016 – Horizon Discovery Group PLC had its “buy” rating reaffirmed by analysts at Numis Securities Ltd. They now have a GBX 260 ($3.39) price target on the stock.
  • 9/20/2016 – Horizon Discovery Group PLC had its price target lowered by analysts at Panmure Gordon from GBX 270 ($3.52) to GBX 205 ($2.68). They now have a “buy” rating on the stock.
  • 9/14/2016 – Horizon Discovery Group PLC had its “speculative buy” rating reaffirmed by analysts at Beaufort Securities.
  • 9/13/2016 – Horizon Discovery Group PLC had its “buy” rating reaffirmed by analysts at Panmure Gordon. They now have a GBX 270 ($3.52) price target on the stock.
  • 9/7/2016 – Horizon Discovery Group PLC had its “buy” rating reaffirmed by analysts at Numis Securities Ltd. They now have a GBX 252 ($3.29) price target on the stock.
  • 9/2/2016 – Horizon Discovery Group PLC had its “speculative buy” rating reaffirmed by analysts at Beaufort Securities.
  • 9/1/2016 – Horizon Discovery Group PLC had its “buy” rating reaffirmed by analysts at Numis Securities Ltd. They now have a GBX 252 ($3.29) price target on the stock.
  • 9/1/2016 – Horizon Discovery Group PLC had its “buy” rating reaffirmed by analysts at Panmure Gordon. They now have a GBX 270 ($3.52) price target on the stock.

Shares of Horizon Discovery Group PLC (LON:HZD) opened at 156.00 on Thursday. The stock’s market capitalization is GBX 146.78 million. Horizon Discovery Group PLC has a 52-week low of GBX 125.00 and a 52-week high of GBX 188.06. The company’s 50 day moving average price is GBX 160.22 and its 200 day moving average price is GBX 160.62.

Horizon Discovery (LSE: HZD) is a world-leading gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. Horizon’s proprietary gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.

Receive News & Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.